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Abstract
Background:  More than 6 million Americans have undiagnosed diabetes. Several national
organizations endorse screening for diabetes by physicians, but actual practice is poorly
understood. Our objectives were to measure the rate, the predictors and the results of glucose
testing in primary care, including rates of follow-up for abnormal values.
Methods: We conducted a retrospective cohort study of 301 randomly selected patients with no
known diabetes who received care at a large academic general internal medicine practice in New
York City. Using medical records, we collected patients' baseline characteristics in 1999 and
followed patients through the end of 2002 for all glucose tests ordered. We used multivariate
logistic regression to measure associations between diabetes risk factors and the odds of glucose
testing.
Results: Three-fourths of patients (78%) had at least 1 glucose test ordered. Patient age (≥45 vs.
<45 years), non-white ethnicity, family history of diabetes and having more primary care visits were
each independently associated with having at least 1 glucose test ordered (p < 0.05), whereas
hypertension and hyperlipidemia were not. Fewer than half of abnormal glucose values were
followed up by the patients' physicians.
Conclusion: Although screening for diabetes appears to be common and informed by diabetes
risk factors, abnormal values are frequently not followed up. Interventions are needed to trigger
identification and further evaluation of abnormal glucose tests.
Background
Of the 20.8 million Americans with diabetes, 6.2 million
(30%) are unaware of their diagnosis [1]. It is unclear why
nearly one-third of patients with diabetes are undiag-
nosed. One potential reason could be insufficient screen-
ing for diabetes in the context of medical care. Insufficient
screening may occur, because there is no consensus from
national guidelines on who should be screened [2-4].
Patients could also be undiagnosed if screening is done
but abnormal values are not recognized and addressed.
Published: 12 July 2006
BMC Health Services Research 2006, 6:87 doi:10.1186/1472-6963-6-87
Received: 03 April 2006
Accepted: 12 July 2006
This article is available from: http://www.biomedcentral.com/1472-6963/6/87
© 2006 Kern et al; licensee BioMed Central Ltd.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.BMC Health Services Research 2006, 6:87 http://www.biomedcentral.com/1472-6963/6/87
Page 2 of 6
(page number not for citation purposes)
The extent of diabetes screening in primary care and the
patient characteristics associated with screening are not
well understood. Some previous studies were limited by
reliance on patients' self-reports of being screened [5,6],
which may not be accurate. Other studies considered
actual testing, but measured this in populations that were
predominantly young [7], had few non-whites [8], or
were restricted to managed care settings [8].
Our primary objectives were: 1) to measure the rate of
actual glucose testing among patients without known dia-
betes, using data from a diverse patient population in a
mixed payer setting; and 2) to assess the short-term out-
comes of testing, including the rate of follow-up for
abnormal results. Our secondary objectives were to deter-
mine which patient characteristics are associated with any
glucose testing and to determine whether the practice pat-
terns observed resemble national guidelines.
Methods
Study design and patients
We conducted a retrospective cohort study of patients
who were randomly selected from a large outpatient gen-
eral internal medicine practice affiliated with an academic
health center in New York City. This practice has an elec-
tronic medical record, which captures all appointments,
test orders, laboratory results and progress notes. There
was no systematic screening program for diabetes in place
at the time of this study, nor did the electronic medical
record have specific flags for episodes of diabetes screen-
ing. The Institutional Review Board of the Weill Medical
College of Cornell University approved this research.
We generated electronically a list of patients who had an
initial visit in 1999 with a full-time attending physician
(i.e. one who spent ≥80% effort on patient care per week).
The rationale for restricting our sample to those with ini-
tial, or first, visits was that initial visits often have more
complete data for diabetes risk factors, including family
history. The alternative approach of tracing existing
patients back to their initial visits was considered less fea-
sible (due to transitions from paper to electronic medical
records) and more prone to errors in data collection. We
randomly sampled from the list of initial visits and
reviewed medical records until we found at least 300
patients who met our inclusion criteria: we required that
patients have at least 2 additional visits by the end of
2002, and we excluded patients who were younger than
20 years of age, had known diabetes at the initial visit, or
were pregnant at any time during the study period. Our
target sample size, based on a prior study of self-reported
diabetes screening [5], provided 80% power to determine
a 15% absolute difference between the rate of glucose test-
ing among patients with 0–1 risk factors and the rate of
glucose testing among patients with 2 or more risk factors
[9].
Data collection
Two trained abstractors collected data manually from
patients' electronic medical records. Data collected from
the initial visit included demographic data, medical his-
tory, and physical exam findings. Each patient was then
followed over time for all glucose tests ordered in the out-
patient setting, until a new diagnosis of diabetes was
made or until December 31, 2002, whichever came first.
Thus, most patients were followed for at least 3 years, a
strategy which is consistent with the screening interval rec-
ommended by the American Diabetes Association (ADA)
[2] and which was chosen to maximize the study's ability
to capture glucose testing for patients. If a primary care
physician documented that a patient had been diagnosed
with diabetes by an outside physician or during a hospi-
talization since the last visit, we counted that as a diagno-
sis and did not require the primary care physician to do
further diagnostic testing. We recorded the number of vis-
its and the number of different primary care physicians
seen by each patient over the observation period. For each
glucose test ordered, we recorded: the type of glucose test;
the patients' fasting state during the test; polyuria or poly-
dipsia reported at the time of the test; the physician's
stated reason, if any, for ordering the test; the glucose
value; the physician's interpretation of the glucose value;
and the physician's subsequent action.
Inter-rater reliability
Using duplicate data collection for a random 10% sub-
sample of the patients, we calculated percent agreement
between data abstractors. Percent agreement was high for
glucose orders (94%), type of glucose test (98%), fasting
state (98%), presence of polyuria or polydipsia (98%),
and action following glucose testing (100%). Percent
agreement was lower for the reason for testing (66%) and
for glucose interpretation (74%).
Statistical analysis
We used descriptive statistics based on complete data to
characterize the patients in our sample, the patterns of
glucose testing and rates of follow-up. We considered dif-
ferent cutoffs for clinically significant glucose values,
based on the ADA's interpretation of fasting values (≥126
mg/dl for diabetes [2], 110–125 mg/dl for the old defini-
tion of impaired fasting glucose [10], and 101–125 mg/dl
for the new definition of impaired fasting glucose [2,11]).
If glucose values were random or were not documented as
fasting, we still considered values in these ranges to be
potentially abnormal, because they should trigger repeat
testing to confirm that a patient's fasting values are in the
normal range. When calculating rates of follow-up for
abnormal values, we conducted a sensitivity analysis toBMC Health Services Research 2006, 6:87 http://www.biomedcentral.com/1472-6963/6/87
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assess the effect of continuity, restricting the sample to
only those who had all visits with the same physician.
We considered 10 potential patient predictors of glucose
testing: age, gender, ethnicity, insurance type, family his-
tory of diabetes, hypertension, high cholesterol, body
mass index (BMI), the number of visits during the study
period, and continuity (whether all visits were with the
same physician). Only 1 patient had a documented his-
tory of gestational diabetes and no patients had a docu-
mented history of impaired fasting glucose; thus, these
variables were not considered in prediction models. For
each variable included in the model, values were missing
for <10% of patients, except for ethnicity (missing for
17%) and height (missing for 59%). To address this, we
used multiple imputation to generate 5 complete versions
of our dataset, with some variation in the imputed values
across versions [12,13]. We then analyzed each imputed
dataset and combined estimates of odds ratios (OR) and
95% confidence intervals (CI) by applying Rubin's for-
mula [14].
We used bivariate and multivariate logistic regression to
measure associations between patient characteristics and
the odds of having at least 1 glucose test ordered over the
study period. Because the proportion of data missing for
height was large, we generated 2 different multivariate
models: the first model included weight alone (without
height) and the second model included BMI (reflecting
both height and weight). Results were similar for the
bivariate models and for the first multivariate model
whether we used complete or imputed data. We therefore
display results based on imputed data.
In addition, we generated a composite variable for the
number of diabetes risk factors each patient had [age 45
years or older, non-white ethnicity, family history of dia-
betes, hypertension, high cholesterol, and overweight or
obese (BMI ≥ 25)]. We calculated the odds of glucose test-
ing for each additional risk factor, and we separately cal-
culated the odds of glucose testing for 2 or more risk
factors vs. 0–1 risk factors.
We determined the proportions of patients who would be
eligible for screening based on the criteria set by national
guidelines. Patients were considered eligible for screening
by the ADA if they were 45 years of age or older, or were
overweight or obese and had 1 or more of the other dia-
betes risk factors listed above [2]. Patients were considered
eligible for screening by the Centers for Disease Control
and Prevention (CDC) if they were 25 years of age or older
[3], and by the U.S. Preventive Services Task Force (USP-
STF) if they had hypertension and/or hyperlipidemia
[4,15]. Among those eligible for screening by each guide-
line, we calculated the proportion that had at least 1 glu-
cose test ordered.
We considered p-values ≤ 0.05 to be significant. Data




Our electronic search identified 3543 patients as having
had initial visits in 1999 with full-time attending physi-
cians. We reviewed medical records for 621 (18%) of
these patients, in order to find 301 who met criteria for
inclusion. The other 320 (52%) were excluded for the fol-
lowing reasons: did not actually have an initial visit in
1999 (n = 27), did not have 2 additional visits before the
end of 2002 (n = 250), age under 20 years (n = 7), known
diabetes at the initial visit (n = 19), pregnancy (n = 10)
and missing medical records (n = 7).
The 301 included patients together had 19 different pri-
mary care physicians. The average time from the first to
last visit in the study period was 2.3 years, with an average
of 6 primary care visits per patient. More than half of
patients (57%) saw their own primary care physician for
every visit. Patients had an average age of 40 years (Table
1). Sixty percent were female, and 41% were of minority
ethnicity. Most patients (87%) had commercial insur-
ance. Approximately 1 in 5 had a family history of diabe-
tes. Very few women (1%) had a history of gestational
diabetes. A history of hypertension (10%) or high choles-
Table 1: Characteristics of patients without known diabetes
Characteristic N = 301*
Age, mean years (sd) 40 (14)
Female, % 60
Ethnicity










Family history of diabetes, % 22
History of gestational diabetes (women only), % 1
History of hypertension, % 10
History of high cholesterol, % 8
Height, mean inches (sd) 67 (4)
Weight, mean pounds (sd) 162 (41)
* Variables with missing data (and number of missing values): age (0), 
gender (0), ethnicity (50), insurance (7), family history (20), gestational 
diabetes (24 women), hypertension (9), high cholesterol (9), height 
(179), weight (24). Percentages may not total 100 due to rounding.BMC Health Services Research 2006, 6:87 http://www.biomedcentral.com/1472-6963/6/87
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terol (8%) was not uncommon. The average height and
weight were 67 inches and 162 pounds, respectively,
which is equivalent to an average BMI of 25.
Characteristics of glucose tests
A total of 559 glucose tests were ordered over the study
period. The number of tests per patient ranged from 0 to
10, with a mean of 1.9 tests (median 2 tests) per patient.
More than three-fourths of patients (78%) had a least 1
glucose test ordered. Of the glucose tests ordered, 90%
were part of chemistry panels. For 3% of tests, physicians
documented that patients were fasting, and for 11% of
tests physicians documented that they were ordered for
screening purposes.
Of the 559 glucose tests ordered, 466 (83%) were done.
The proportion of potentially abnormal values depended
on the cutoff chosen: 65 (14%) were ≥101 mg/dl, 26 (6%)
were ≥110 mg/dl, and 15 (3%) were ≥126 mg/dl. Of the
65 potentially abnormal values (≥101 mg/dl), only 1 was
obtained following a visit for polyuria or polydipsia.
When the glucose value was 101–109 mg/dl in asympto-
matic patients, physicians reported that the value was nor-
mal in 35% of cases and did not document any
interpretation for the remainder of cases. No documented
follow-up occurred for any of these values. When the glu-
cose value was 110–125 mg/dl in asymptomatic patients,
physicians recorded that these values were normal (14%)
or potentially erroneous (43%), or they did not record
any interpretation (43%). For these values, physicians
repeated the test (43%) or did not indicate any further
action (57%). For the small number of glucose values
≥126 mg/dl in asymptomatic patients, physicians inter-
preted these as normal (17%), representing diabetes
(25%) or potentially erroneous (25%), or they did not
document any interpretation (33%). For these values,
physicians repeated the test (31%), prescribed a change in
diet (15%), prescribed a change in both diet and exercise
(8%), or did not indicate any subsequent action (46%).
Patients were more likely to have some follow-up action
for a glucose value ≥110 mg/dl if every visit was with the
patient's primary care physician (69% follow-up rate)
than if at least 1 visit was with a covering physician (14%
follow-up rate; p = 0.02).
Predictors of glucose testing and adherence to guidelines
In bivariate models, 7 patient characteristics were statisti-
cally significant predictors of glucose testing (Table 2).
Four of these remained statistically significant in both
multivariate models (Table 2). Older age (≥45 years),
non-white ethnicity, family history of diabetes, and hav-
ing more visits each independently increased the adjusted
odds of having at least 1 glucose test ordered. The magni-
tude of these associations was sizable; for example, being
45 years of age or older increased the odds of glucose test-
ing 12-fold, being non-white increased the odds of glu-
cose testing nearly 4-fold, and having a family history of
diabetes increased the odds of glucose testing 3-fold.
Model 1 (adjusting for weight) and Model 2 (adjusting for
BMI) were similar, except that female gender reached sta-
tistical significance as a predictor of glucose testing only in
Model 2, decreasing the adjusted odds of testing (Table 2).
Also in Model 2, as BMI increased, the odds of glucose
testing increased, but this association did not reach statis-
tical significance. Of note, neither hypertension nor high
cholesterol was an independent predictor of glucose test-
ing in either multivariate model.
For each additional diabetes risk factor a patient had, the
odds of glucose testing increased 3-fold, adjusting for gen-
der, insurance, number of visits and continuity (OR 3.06,
95% CI 1.99 – 4.70). Patients with 2 or more risk factors
Table 2: Predictors of having at least 1 glucose test ordered, among 301 patients without known diabetes
Odds Ratio (95% Confidence Interval)
Predictor Bivariate Models Multivariate Model 1 Multivariate Model 2
Age (≥45 vs. <45 years) 14.00 (4.27 – 45.89)* 12.60 (3.51 – 45.23)* 12.36 (3.41 – 44.79)*
Gender (female vs. male) 0.54 (0.30 – 0.97)* 0.48 (0.22 – 1.04)† 0.45 (0.21 – 0.93)*
Ethnicity (non-white vs. white) 3.05 (1.55 – 6.01)* 3.66 (1.66 – 8.06)* 3.71 (1.68 – 8.20)*
Insurance (commercial vs. other) 0.41 (0.14 – 1.19) 1.61 (0.41 – 6.31) 1.76 (0.43 – 7.16)
Family history of diabetes (yes vs. no) 3.01 (1.27 – 7.11)* 3.14 (1.19 – 8.28)* 2.98 (1.12 – 7.93)*
Hypertension (yes vs. no) 7.92 (1.20 – 52.14)* 1.45 (0.18 – 11.60) 1.22 (0.15 – 9.82)
High cholesterol (yes vs. no) 1.30 (0.43 – 3.88) 0.72 (0.18 – 2.80) 0.71 (0.18 – 2.78)
Weight (per 10 pounds) 1.13 (1.04 – 1.22)* 1.07 (0.97 – 1.19) ---
Body mass index (per unit, kg/m2) 1.13 (1.06 – 1.21)* --- 1.08 (1.00 – 1.18)†
Number of visits observed (per visit) 1.32 (1.15 – 1.53)* 1.34 (1.13 – 1.60)* 1.33 (1.12 – 1.58)*
All visits with same physician (yes vs. no) 1.47 (0.85 – 2.55) 1.38 (0.69 – 2.75) 1.40 (0.70 – 2.80)
* p < 0.05. † p < 0.10.BMC Health Services Research 2006, 6:87 http://www.biomedcentral.com/1472-6963/6/87
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were approximately 10 times as likely to have glucose tests
ordered as patients with 0 or 1 risk factor, adjusting for
gender, insurance, number of visits and continuity (OR
9.57, 95% CI 3.93 – 23.31).
Among patients eligible for diabetes screening according
to each national guideline, the rates of glucose testing
were high: 96% for the ADA, 82% for the CDC, and 90%
for the USPSTF.
Discussion
In this study of patients without known diabetes, the
majority (78%) had 1 or more glucose tests ordered over
a 3-year period. One in seven glucose values (14%) was
potentially abnormal. When the glucose value was 110
mg/dl or greater, physicians interpreted these as normal
16% of the time and did not indicate plans for any subse-
quent work-up 50% of the time.
Although glucose testing does not always represent inten-
tional screening, the patterns of testing were not random.
Selected risk factors for diabetes (age 45 years and older,
non-white ethnicity and family history of diabetes) inde-
pendently increased the odds of glucose testing. Hyper-
tension and hyperlipidemia were not associated with
glucose testing, even though chemistry panels that include
glucose are often ordered to monitor these diseases. These
findings suggest that intentional screening for diabetes is
occurring, even if physicians are not documenting this
reason for glucose testing.
Glucose testing most closely resembled the guidelines of
the ADA, based on the high rate of testing for eligible
patients (97%) and the strong association of ADA-specific
selection factors (such as non-white ethnicity and family
history) with glucose testing. However, "adherence" to the
CDC and USPSTF guidelines were also high, indicating
that many of the risk factors used to select patients for
screening are correlated with each other (age with hyper-
tension, for example).
Our study builds on the findings of previous research.
Ealovega and colleagues found that 69% of primary care
patients received glucose testing over a 3-year period in a
managed care setting [8], which is consistent with our
finding of 78%. Ealovega and colleagues also found that
only 38% of abnormal results received appropriate fol-
low-up, consistent with our finding of 50% [8]. Other
investigators found that glucose testing was associated
with age [5] and family history of diabetes [6,7]. However,
several of these previous analyses were limited by incom-
plete adjustment for potential confounders [5,7]. Ours
was the only study to find an independent effect of ethnic-
ity on the odds of glucose testing. Our finding that hyper-
tension and hyperlipidemia were not independent
predictors of glucose testing is in contrast to others' [8].
None of the previous studies specifically compared prac-
tice patterns to national screening guidelines.
Failure to recognize abnormal glucose values represents a
missed opportunity to identify and treat incident diabetes
or pre-diabetes, with timely treatment of pre-diabetes hav-
ing the potential to prevent or delay the onset of diabetes
[16]. That follow-up rates were higher for patients who
had all visits with the same primary care physician is
intriguing but based on a relatively small sample size and
warrants replication in larger studies. There are several rea-
sons why physicians may not act upon abnormal values:
they may not have seen the values, may not have recog-
nized their importance, or may have been giving their
attention to competing demands. Indeed, a study that sur-
veyed physicians about test result management in general
found that only 52% of respondents reported keeping a
record of tests that they had ordered and 83% acknowl-
edged delays in recognizing and acting upon abnormal
results, saying that they had reviewed at least 1 test result
in the last 2 months that they "wished they had seen ear-
lier" [17].
This study had several strengths. We used electronic orders
for actual glucose tests, rather than patients' self-report of
testing. We included an ethnically diverse patient popula-
tion, with a proportion of ethnic minorities (41%) similar
to that in the U.S. overall (37%) [18]. We followed
patients over time, allowing for multiple primary care vis-
its and approximating the 3-year screening interval sug-
gested by the ADA. In addition, we used the rigorous
statistical method of multiple imputation to account for
missing data.
Several limitations merit discussion. First, height was
missing for a substantial proportion of patients; however,
results were similar when the multivariate model was per-
formed with and without this variable. Second, we did not
have enough power to adjust for clustering by physician,
making it possible that some physicians' practice styles
weighted the results more heavily than others'. Third, the
study took place in one institution that may not be gener-
alizable to other settings. Fourth, this study may actually
underestimate the proportion of abnormal glucose val-
ues, because glucose values may be falsely low if the sam-
ples are not processed promptly. Fifth, patients who came
for initial visits in 1999 may vary from patients who came
only for subsequent visits that year. Sixth, it is possible
that some patients with known diabetes did not report
their condition at the initial visit, although this is unlikely
because only 1 patient was diagnosed with diabetes –
based on an abnormal glucose – after the initial visit; most
patients diagnosed with diabetes were diagnosed after
subsequent visits. Finally, as in all studies that examinePublish with BioMed Central    and   every 
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medical records, some results were dependent on what
physicians documented, although we minimized this by
including in the analysis any glucose test ordered rather
than only glucose tests for which screening was docu-
mented as the purpose.
Conclusion
In conclusion, the majority of patients received glucose
tests, and testing appeared to be informed by diabetes risk
factors. These findings decrease the probability that undi-
agnosed diabetes is due to insufficient screening in pri-
mary care. However, lack of recognition and follow-up for
abnormal glucose values may cause unnecessary delays in
diagnosis and treatment. Interventions are needed not to
increase the rate of testing but to trigger further evaluation
of patients who have abnormal results.
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